Zydus receives final approval from the USFDA for Fesoterodine Fumarate Extended-Release Tablets

Ahmedabad, 05 October 2017

Zydus Cadila has received the final approval from the USFDA to market Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. Fesoterodine is used to treat an overactive bladder with symptoms of urinary frequency, urgency, and incontinence.

The sales of Fesoterodine Fumarate Extended-Release Tablets are estimated at $195.5 million. *Source: IMS Health, IMS National Sales Perspective Audit, MAT August 2017, extracted October 2017.*

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

***